The UK and US have forged a important commercial pact that will preserve no import taxes on UK pharmaceutical exports entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase funding on medicines through the NHS. This move guarantees that duties on these vital goods will be held at nothing for a timeframe of three years.
This deal follows earlier warnings to significantly raise duties on branded pharmaceutical products, with potential rates discussed up to double the cost.
"This agreement between the UK bolsters the international landscape for innovative medicines and brings much-needed fairness to transatlantic medicine commerce," a statement noted.
Commercial Impact
Drugs constitute one of the the United Kingdom's largest export categories to the United States, which is by far the largest destination for large UK drugmakers.
Trade data show that in the year to the end of last September, the UK sold drugs totaling billions to the US. This value made up 17.4% of total UK exports in that period.
"This deal safeguards work, increases capital expenditure and facilitates the UK to become a global hub for medical research," a government official stated.
Detailed NHS Changes
The pact includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. In the past, rebates topped 20%.
Industry Background
This agreement follows a ongoing tension between the sector and the British authorities over spending levels and regulatory access.
These tensions were heightened by arguments that US patients were charged several times more for the same drugs than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or scrapped, while major expansions have been announced toward American operations.
One official stated that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
